Pulmonary fibrosis is still a worldwide medical problem. The pathogenesis and treatment options of the disease are being explored both at home and abroad, and new drugs are constantly coming to market, but they have not yet been able to reverse the progression of fibrosis. Because it is difficult to be cured, pulmonary fibrosis is known as a cancer that is not a cancer. Its insidious onset, rapid disease progression and poor prognosis have made it an invisible killer of middle-aged and elderly people. In recent years, the incidence and death rate of pulmonary fibrosis have been rising, and the age of onset of pulmonary fibrosis is mostly between 40 and 75 years old, higher in men than in women, and higher in urban than in rural areas. The lungs of a healthy person are composed of interstitial lungs and alveoli, which complete the body’s gas exchange function. When suffering from pulmonary fibrosis, the interalveolar connective tissue thickens and hardens, and collagen is excessively deposited, reducing the ability to exchange oxygen and leading to breathing difficulties. If the treatment is not timely or improperly treated, the best treatment period is missed, resulting in smaller and smaller alveolar space, which prevents normal oxygen exchange, making the patient unable to breathe normally and dying from respiratory failure. The clinical symptoms of pulmonary fibrosis vary. Initially, lung injury is often caused by a variety of reasons, such as alveolitis and interstitial pneumonia, which may eventually cause damage to the alveolar epithelium, fibroblast proliferation, interstitial and alveolar structural changes, and pulmonary fibrosis. Pulmonary fibrosis is divided into secondary and idiopathic. Secondary causes can mostly be found in common connective tissue-related pulmonary fibrosis, such as rheumatoid arthritis, systemic lupus erythematosus, desiccation syndrome, dermatomyositis, scleroderma, etc.; occupational factors, such as asbestos workers, coal workers, etc.; diseases caused by, such as chronic obstructive pulmonary disease, etc.; and drug factors, such as methotrexate, amiodarone, etc. In addition, the incidence of pulmonary fibrosis caused by inhalation of dust, inhalation of harmful gases, and smoking is increasing year by year. There are also long-term exposure to dust workers, long-term exposure to irritating gases, such as: chlorine, ammonia, formaldehyde, as well as bird breeding population, exposure to radiation can also cause pulmonary fibrosis. Therefore, we need to check these high-risk groups early and regularly and use some safety measures to prevent the occurrence of pulmonary fibrosis. Idiopathic pulmonary fibrosis is a type of pulmonary fibrosis for which no cause can be found. Pulmonary fibrosis mostly belongs to the category of “pulmonary impotence” in Chinese medicine. Pulmonary impotence is one of the chronic deficiency diseases of the lung, which develops at a later stage in a variety of chronic lung diseases. The clinical manifestations are characterized by coughing and salivation with shortness of breath or coughing and recurrent attacks. The clinical manifestations are characterized by coughing and salivating with shortness of breath or coughing and recurrent attacks. The pathogenesis is mainly due to heat in the upper jiao, lung dryness and fluid injury; or deficiency of lung qi and cold, qi does not transform fluid; deficiency of lung and kidney qi, phlegm and stagnation, resulting in loss of fluid and qi, loss of moistening of the lung, and withering of the lung lobe. There are three major categories of lung deficiency-heat, deficiency-cold and phlegm-stasis, with deficiency-heat evidence being more common. Treatment is always based on the principle of nourishing the lung and generating fluid. If it is difficult to restore the fluid in the lung, the prognosis is usually poor. Chinese medicine has obvious advantages in treating pulmonary fibrosis, which can improve the symptoms of cough and dyspnea and slow down the progress of the disease. The acute stage of pulmonary impotence should be based on resolving phlegm and clearing the lung, and the remission stage should be based on supporting the root of the disease and dispelling the evil. During the period of alveolitis, on the basis of glucocorticoid combined with immunosuppressive therapy, Chinese herbal medicine is applied to regulate immune function, reduce the toxic side effects of hormones, prevent fibrosis formation, and improve the prognosis of the disease. In the process of clinical evidence, I have treated many patients with pulmonary fibrosis, basically all of them came here for TCM treatment when the effect of western medical treatment was not obvious. Generally, we use TCM combined with TCM characteristic treatment as the main treatment, supplemented by Western medicine methods for treatment, the efficacy is obvious. Our department has carried out ion introduction, drug irrigation, dou moxibustion and other TCM characteristic physical therapy, which has the effect of warming up qi and blood, tonifying yin and yang, and tonifying lung and kidney, and has obvious effect on pulmonary fibrosis and chronic obstructive pulmonary disease. In addition, early detection and early treatment is the key. More awareness-raising work is done. In the early stage, there are often no clinical symptoms, such as cough and progressive dyspnea, which patients do not pay attention to, and as a result, the best treatment effect is missed. By the late stage of the disease, the work is often lost. I have some patients who, after adhering to the combined TCM treatment with TCM specialties, have relieved their symptoms and regained their courage for life. When the chest CT was repeated, the grid-like shadows were significantly reduced compared to before. Seeing the smiling faces of patients always gives me a sense of accomplishment as a doctor.